Veloxis Pharma Inc v. Sun Pharmaceutical Industries Ltd

I. Executive Summary and Procedural Information

• Parties & Counsel:
  • Plaintiff: Veloxis Pharmaceuticals, Inc. (Delaware)
  • Defendant: Sun Pharmaceutical Industries Ltd. (India) and Sun Pharmaceutical Industries, Inc. (Delaware)
  • Plaintiff's Counsel: Morris, Nichols, Arsht & Tunnell LLP
• Case Identification: 1:24-cv-00726, D. Del., 05/16/2025
• Venue Allegations: Venue is alleged to be proper in the District of Delaware because Defendant Sun Pharmaceutical Industries, Inc., is a Delaware corporation and therefore resides in the district.
• Core Dispute: Plaintiff alleges that Defendants' Abbreviated New Drug Application (ANDA) seeking approval to market generic versions of Plaintiff's ENVARSUS XR® (tacrolimus) infringes eight U.S. patents related to extended-release and stabilized tacrolimus formulations.
• Technical Context: The technology concerns pharmaceutical formulations of tacrolimus, an immunosuppressant drug critical for preventing organ rejection in transplant patients, designed to improve its stability and provide an extended-release profile for once-daily administration.
• Key Procedural History: The action arises under the Hatch-Waxman Act, triggered by Defendants' submission of ANDA No. 215836 to the FDA. The complaint notes that Defendants' ANDA includes a Paragraph IV Certification asserting non-infringement and/or invalidity of the asserted patents, which are listed in the FDA's Orange Book for the brand-name drug ENVARSUS XR®.

Case Timeline

Date	Event
2008-07-08	Priority Date for '998, '918, '190, '199, '081, '331, '823, and '103 Patents
2014-04-01	U.S. Patent No. 8,685,998 Issued
2017-01-24	U.S. Patent No. 9,549,918 Issued
2019-01-01	U.S. Patent No. 10,166,190 Issued
2020-12-15	U.S. Patent No. 10,864,199 Issued
2021-09-07	U.S. Patent No. 11,110,081 Issued
2021-09-21	U.S. Patent No. 11,123,331 Issued
2022-08-23	U.S. Patent No. 11,419,823 Issued
2024-05-08	Defendants' May 8 Notice Letter Sent
2024-09-10	U.S. Patent No. 12,083,103 Issued
2025-05-16	Complaint Filed

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 8,685,998 - "Tacrolimus for Improved Treatment of Transplant Patients"

The Invention Explained

• Problem Addressed: The patent describes tacrolimus administration as challenging due to its low and variable bioavailability, which necessitates frequent dose adjustments based on blood monitoring ʼ998 Patent, col. 1:52-59 Conventional formulations can also lead to high peak blood concentrations, which are associated with significant nephrotoxic and neurotoxic side effects ʼ998 Patent, col. 2:22-28
• The Patented Solution: The invention is an extended-release oral dosage form of tacrolimus designed for once-daily administration ʼ998 Patent, abstract It aims to release the drug over a "very extended period of time" to provide a high bioavailability and an improved pharmacokinetic profile, characterized by lower peak concentrations (Cmax) and higher minimum concentrations (Cmin) compared to conventional immediate-release products ʼ998 Patent, col. 1:19-24 ʼ998 Patent, Fig. 3
• Technical Importance: This approach sought to improve patient safety by reducing peak-concentration-related side effects and enhance treatment efficacy and compliance through a more stable drug exposure profile and a simplified once-daily dosing regimen ʼ998 Patent, col. 4:11-25

Key Claims at a Glance

• The complaint asserts at least Claim 1 Compl. ¶37
• Essential elements of independent Claim 1 include:
  • A method of providing immunosuppressive treatment to a transplant patient in need thereof
  • comprising administering once daily in the evening to said patient
  • an extended release pharmaceutical composition comprising tacrolimus
  • wherein the composition provides a Cmax that is at the most about 30 ng/ml and a Cdiff of about 20 ng/mL or less.
• The complaint does not explicitly reserve the right to assert dependent claims for this patent.

U.S. Patent No. 9,549,918 - "Stabilized Tacrolimus Composition"

The Invention Explained

• Problem Addressed: The patent family addresses the chemical instability of tacrolimus, particularly in solid dispersion formulations where the drug molecules have increased motility ʼ190 Patent, col. 3:53-59 This instability can lead to the formation of degradation products, such as the isomer 8-epitacrolimus, which is undesirable in a pharmaceutical product ʼ190 Patent, col. 3:11-16 ʼ190 Patent, col. 4:16-19
• The Patented Solution: The invention provides a pharmaceutical composition that stabilizes tacrolimus by incorporating a "stabilizing agent" into the formulation ʼ918 Patent, abstract This agent, which may be a metal-chelating organic acid like tartaric or citric acid, creates a pH environment below 7 (as measured after re-dispersion in water), which prevents or reduces the formation of degradation products upon storage ʼ918 Patent, col. 3:20-28 ʼ918 Patent, col. 8:5-12
• Technical Importance: By controlling chemical degradation, the invention enables the creation of stable, solid-dispersion tacrolimus formulations that can maintain their integrity and purity throughout their shelf-life, a critical requirement for regulatory approval and patient safety (ʼ190 Patent, col. 3:17-22).

Key Claims at a Glance

• The complaint asserts at least Claim 1 Compl. ¶48
• Essential elements of independent Claim 1 include:
  • A sustained release tablet comprising (i) a dispersion of tacrolimus, (ii) 8-epitacrolimus, and (iii) a metal chelating agent that is an organic acid
  • wherein the tacrolimus is the sole active ingredient in the tablet
  • and the tablet comprises a sufficient amount of the metal chelating agent such that the tablet comprises less than 0.5% by weight of the 8-epitacrolimus after 12 weeks of storage at 25° C. and 60% relative humidity, based upon 100% total weight of tacrolimus.
• The complaint does not explicitly reserve the right to assert dependent claims for this patent.

U.S. Patent No. 10,166,190 - "Stabilized Tacrolimus Composition"

• Technology Synopsis: The patent relates to stabilizing tacrolimus in a solid dispersion formulation to prevent chemical degradation ʼ190 Patent, background The solution involves incorporating a stabilizing agent, such as an organic acid, capable of providing a pH below 7 upon re-dispersion in water, which reduces the formation of degradation products like 8-epitacrolimus ʼ190 Patent, abstract
• Asserted Claims: The complaint asserts at least Claim 1 Compl. ¶59
• Accused Features: Defendants' ANDA Products are alleged to infringe Compl. ¶59

U.S. Patent No. 10,864,199 - "Tacrolimus for Improved Treatment of Transplant Patients"

• Technology Synopsis: This patent describes an extended-release oral dosage form of tacrolimus for once-daily administration, intended to improve the drug's pharmacokinetic profile ʼ199 Patent, abstract The formulation is designed to provide high bioavailability while reducing peak blood concentrations and fluctuations, thereby aiming to minimize side effects and improve patient outcomes ʼ199 Patent, col. 2:51-62
• Asserted Claims: The complaint asserts at least Claim 14 Compl. ¶70
• Accused Features: Defendants' ANDA Products are alleged to infringe Compl. ¶70

U.S. Patent No. 11,110,081 - "Tacrolimus for Improved Treatment of Transplant Patients"

• Technology Synopsis: This patent relates to an extended-release oral dosage form of tacrolimus for once-daily immunosuppressive treatment ʼ081 Patent, abstract The technology aims to release the drug over a very extended period to achieve high bioavailability and an improved pharmacokinetic profile compared to conventional dosage forms, featuring reduced peak concentrations and less variability ʼ081 Patent, col. 2:51-62
• Asserted Claims: The complaint asserts at least Claim 1 Compl. ¶80
• Accused Features: Defendants' ANDA Products are alleged to infringe Compl. ¶80

U.S. Patent No. 11,123,331 - "Tacrolimus for Improved Treatment of Transplant Patients"

• Technology Synopsis: The patent describes an extended-release oral dosage form of tacrolimus for once-daily use, designed to provide an improved pharmacokinetic profile ʼ331 Patent, abstract The formulation aims to deliver the drug over an extended period to increase bioavailability while decreasing peak concentrations, thereby improving the safety and efficacy of the treatment ʼ331 Patent, col. 2:51-62
• Asserted Claims: The complaint asserts at least Claim 1 Compl. ¶90
• Accused Features: Defendants' ANDA Products are alleged to infringe Compl. ¶90

U.S. Patent No. 11,419,823 - "Stabilized Tacrolimus Composition"

• Technology Synopsis: This patent addresses the chemical degradation of tacrolimus in pharmaceutical compositions, particularly solid dispersions ʼ823 Patent, background The invention is a stable composition containing a stabilizing agent, such as an organic acid, that maintains a pH below 7 to prevent the formation of impurities like 8-epitacrolimus ʼ823 Patent, abstract
• Asserted Claims: The complaint asserts at least Claim 1 Compl. ¶100
• Accused Features: Defendants' ANDA Products are alleged to infringe Compl. ¶100

U.S. Patent No. 12,083,103 - "Tacrolimus for Improved Treatment of Transplant Patients"

• Technology Synopsis: This patent pertains to an extended-release oral dosage form of tacrolimus for once-daily immunosuppressive treatment ʼ103 Patent, abstract The formulation is designed to release the drug over a very extended period to achieve an improved pharmacokinetic profile with high bioavailability, reduced peak concentrations, and less variability compared to conventional formulations ʼ103 Patent, col. 2:51-62
• Asserted Claims: The complaint asserts at least Claim 1 Compl. ¶108
• Accused Features: Defendants' ANDA Products are alleged to infringe Compl. ¶108

III. The Accused Instrumentality

Product Identification

• The accused instrumentalities are Defendants' 0.75 mg, 1 mg, and 4 mg extended-release tablets of tacrolimus ("Defendants' ANDA Products"), for which Defendants submitted Abbreviated New Drug Application No. 215836 to the FDA Compl. ¶1

Functionality and Market Context

• The complaint alleges that by filing the ANDA, Defendants have represented to the FDA that their proposed generic products have the same active ingredient, dosage form, route of administration, and strengths as Plaintiff's ENVARSUS XR® product Compl. ¶28
• The complaint further alleges that Defendants' ANDA Products are represented as bioequivalent to ENVARSUS XR® and are intended for the same approved indications, namely the prophylaxis of organ rejection in kidney transplant patients Compl. ¶28 The products are positioned to be generic competitors to ENVARSUS XR® upon FDA approval Compl. ¶2

No probative visual evidence provided in complaint.

IV. Analysis of Infringement Allegations

The complaint alleges that Defendants' ANDA Products, and/or their use as directed by the proposed product label, will infringe the asserted claims either literally or under the doctrine of equivalents Compl. ¶37 Compl. ¶48 The complaint does not provide a detailed, element-by-element infringement analysis or include claim charts. The allegations are made on "information and belief."

Identified Points of Contention

• Scope Questions: The infringement analysis for the '998 Patent may raise questions regarding the method claim element "administering once daily in the evening" ʼ998 Patent, claim 1 The dispute could center on whether Defendants' proposed product label instructs or encourages evening administration to an extent that supports a finding of induced infringement.
• Technical Questions: For the '918 Patent, a key technical question will be whether Defendants' ANDA Products actually meet the stability limitation of Claim 1, which requires that the tablet comprise "less than 0.5% by weight of the 8-epitacrolimus after 12 weeks of storage at 25° C. and 60% relative humidity" ʼ918 Patent, claim 1 This presents a direct factual question that will likely be resolved through testing and expert analysis of Defendants' formulation. A second question is whether Defendants' formulation contains "a metal chelating agent that is an organic acid," as required by the claim.

V. Key Claim Terms for Construction

The Term: "administering once daily in the evening" (from Claim 1 of the '998 Patent)

• Context and Importance: This term is central to the method claim of the '998 Patent. Its construction will be critical for determining induced infringement, as the analysis will focus on whether Defendants' proposed product label encourages or instructs administration in a manner that falls within the scope of "in the evening."
• Intrinsic Evidence for Interpretation:
  • Evidence for a Broader Interpretation: The patent does not appear to provide an explicit definition of "evening," which may suggest the term should be given its plain and ordinary meaning, potentially encompassing a wide range of afternoon or nighttime hours.
  • Evidence for a Narrower Interpretation: Practitioners may argue that the term should be limited by the context of clinical studies or examples described in the patent, if any specify particular administration times, to argue for a more constrained definition. The specification's focus on a 24-hour dosing interval and maintaining therapeutic trough levels may also inform the temporal scope of the term.

The Term: "a sufficient amount of the metal chelating agent such that the tablet comprises less than 0.5% by weight of the 8-epitacrolimus after 12 weeks of storage" (from Claim 1 of the '918 Patent)

• Context and Importance: This is a functional limitation that defines the amount of the stabilizing agent by the result it achieves. The infringement analysis will turn on whether Defendants' product, when tested, exhibits this level of stability. Practitioners may focus on this term because it links the composition's structure ("metal chelating agent") to a functional outcome ("less than 0.5%... 8-epitacrolimus").
• Intrinsic Evidence for Interpretation:
  • Evidence for a Broader Interpretation: The claim language is result-oriented, suggesting that any amount of a qualifying agent that achieves the stated stability outcome falls within the claim scope. The specification provides examples of stabilizing agents and concentrations that achieve this effect, which a party may argue are merely illustrative, not limiting ʼ918 Patent, col. 11:4-10
  • Evidence for a Narrower Interpretation: A party may argue that "sufficient amount" should be construed in light of the specific embodiments and concentration ranges disclosed in the specification, such as the ranges for tartaric acid from "about 0.01% to about 5% w/w" ʼ918 Patent, col. 8:29-32 It might be contended that amounts outside these disclosed ranges are not "sufficient" within the meaning of the patent.

VI. Other Allegations

Indirect Infringement

• The complaint alleges induced infringement under 35 U.S.C. § 271(b), asserting that upon FDA approval, Defendants will intentionally encourage acts of direct infringement with knowledge of the patents, including through instructions on the product label Compl. ¶41 Compl. ¶52 It also alleges contributory infringement under 35 U.S.C. § 271(c), asserting that Defendants' ANDA Products are especially adapted for an infringing use and have no substantial non-infringing use Compl. ¶42 Compl. ¶53

Willful Infringement

• The complaint alleges that Defendants had knowledge of the patents-in-suit prior to filing their ANDA, which may form the basis for a willfulness allegation Compl. ¶45 Compl. ¶56 The complaint seeks an award of attorneys' fees, alleging the case is "exceptional" under 35 U.S.C. § 285 Compl. ¶46 Compl. ¶57

VII. Analyst's Conclusion: Key Questions for the Case

• A core issue will be one of induced infringement and labeling: For the asserted method claims, such as in the '998 patent, can the instructions and intended use described in the Defendants' proposed product label be shown to actively encourage administration "in the evening," and does that term's scope, as construed by the court, read on the likely real-world use of the generic product?
• A key evidentiary question will be one of composition and stability: For the asserted composition claims, such as in the '918 patent, does the Defendants' formulation contain a "metal chelating agent that is an organic acid," and does it, as a matter of scientific fact, meet the functional stability requirement of producing less than 0.5% 8-epitacrolimus after 12 weeks of storage under the specified conditions?
• A third central question will be one of claim validity: Although Defendants' notice letter did not contest the validity of some patents Compl. ¶¶29-32, it asserted invalidity for the '331 Patent Compl. ¶34 It is highly probable that Defendants will ultimately challenge the validity of all asserted claims on grounds such as obviousness or lack of enablement as the litigation proceeds, making the strength and scope of the prior art a pivotal battleground.